Objectives: Currently, there is limited understanding regarding the prognostic significance of time to progression (TTP) after first remission in multiple myeloma (MM).
Methods: We conducted a retrospective analysis of clinical data from 209 patients with MM. These patients were categorized into ≤ 6 months, ≤ 12 months, ≤ 24 months, > 24 months, 6-12 months, and 12-24 months subgroups based on TTP.
Results: Patients in ≤ 12 months group exhibited shorter median overall survival (OS) and OS-1 compared to those in ≤ 24 months group (61.73 vs 96.10 months, = 0.02; 54.00 vs 74.17 months, = 0.048). ≤ 6 months group exhibited shorter median OS and OS-1 compared to 6-12 months group (33.63 vs 79.60 months, = 0.022; 19.93 vs 65.17 months, = 0.015). Patients in 6-12 months group had shorter median OS and OS-1 compared to those in 12-24 months group (79.60 vs 100.43 months, < 0.001; 65.17 vs 77.17 months, = 0.012).No significant difference in OS was observed between patients in 12-24 months and > 24 months groups. For patients who experienced progression within 12 or 24 months after remission, undergoing autologous hematopoietic stem cell transplantation (ASCT) after progression conferred a median OS and OS-2 advantage over receiving post-progression chemotherapy. Multivariable analysis confirmed that TTP was an independent predictor for OS in patients with MM.
Conclusion: Patients with MM who experience earlier disease progression within 12 months after remission have a worse prognosis, and post-progression ASCT can improve their survival outcomes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/16078454.2024.2448024 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study.
Cancer Immunol Immunother
January 2025
Oncology Unit, Macerata Hospital, Macerata, Italy.
Introduction: Renal cell carcinoma (RCC) is one of the most common types of urogenital cancer. The introduction of immune-based combinations, including dual immune-checkpoint inhibitors (ICI) or ICI plus tyrosine kinase inhibitors (TKIs), has radically changed the treatment landscape for metastatic RCC, showing varying efficacy across different prognostic groups based on the International Metastatic RCC Database Consortium (IMDC) criteria.
Materials And Methods: This retrospective multicenter study, part of the ARON-1 project, aimed to evaluate the outcomes of favorable-risk metastatic RCC patients treated with immune-based combinations or sunitinib.
Case Report: Gutter endoleak embolization in a patient with bilateral common iliac artery aneurysms treated with sandwich parallel grafts.
Front Surg
December 2024
School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
Background: Current guidelines recommend preserving at least one of the bilateral pelvic flows in patients with aortoiliac aneurysms. The sandwich parallel graft, using commercially available devices, provides a viable option for patients who fall outside the instructions for use of iliac branch devices. However, gutter endoleak remains a significant challenge.
View Article and Find Full Text PDFA Prospective Non-interventional Real-World Study of cabozantinib in Pretreated Patients With Advanced Renal Cell Carcinoma Refractory to Vascular Endothelial Growth Factor-Targeted Therapy (CASSIOPE).
Clin Genitourin Cancer
November 2024
Genitourinary Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Background: There is a lack of published data on real-world cabozantinib use in patients with advanced renal cell carcinoma after prior vascular endothelial growth factor (VEGF)-targeted therapy.
Methods: CASSIOPE was a real-world, prospective, multicenter, non-interventional postauthorization safety study of cabozantinib in adult patients with advanced renal cell carcinoma in Europe following prior VEGF-targeted treatment (NCT03419572). Endpoints included cabozantinib utilization (dose modifications due to adverse events [AEs; primary endpoint], dose, dose modifications, and treatment duration), safety, effectiveness (progression-free survival [PFS], overall survival [OS], best overall response [BOR]), and healthcare resource utilization.
The Impact of the COVID-19 Public Health Crisis on the Surgical Management of Abdominal Aortic Aneurysm Rupture.
Ann Vasc Surg
December 2024
Section of Vascular Surgery, Department of Surgery, Michigan Medicine, Ann Arbor, MI; Jobst Vascular Institute, Toledo, OH.
Objectives: The COVID-19 epidemic introduced significant systems- and disease-based uncertainty into Abdominal Aortic Aneurysm (AAA) rupture management. The goal of this work was to evaluate whether short-term AAA rupture outcomes during COVID-19 were comparable to pre-COVID era outcomes and to explore the impact of COVID status and COVID era healthcare systems restrictions on AAA rupture outcomes.
Methods: The Vascular Quality Initiative (VQI) database was queried for all ruptured AAAs that underwent intervention from January 1, 2019 to August 31, 2022.
Outcomes of Conservatively Managed Patients With Abdominal Aortic Aneurysm: A Single-Centre Experience.
Cureus
November 2024
Vascular Surgery, Sunderland Royal Hospital, Sunderland, GBR.
Introduction: The results of patients at one hospital who were judged eligible for conservative care of abdominal aortic aneurysms (AAA) are examined in this research. Optimizing patient care and management tactics requires an understanding of the mortality trends and causes of death within this group.
Methodology: Sunderland Royal Hospital carried out a single-center retrospective analysis between May 2018 and January 2024.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!